Why Amyris Is Giving Up on Biodiesel, For Now
By Kevin Bullis,
Technology Review
| 05. 09. 2012
New data show that its products cost more than $30 a gallon to make.
Amyris, a company that uses synthetic biology to make alternatives to conventional petroleum products, recently decided to wind down its biofuels business and focus on selling higher-value products such as cosmetics. Now it's clear why.
Details about Amyris were disclosed during the company's earnings call last night. They show just how far the company is from making biofuel profitably, and illustrate why the company is getting out of the biofuels business—for now.
Shortly after it was founded, Amyris had set out to make biofuel using genetically modified organisms and simple chemistry to turn sugar into a type of oil that's similar to diesel. It had some success making biodiesel for buses in Brazil. But the chemicals produced by the company's microörganisms can be used for other things as well, such as moisturizers and fragrances, that sell for higher prices.
Last night, the company said the average selling price for all its products is $7.70 per liter, or $29 per gallon, far higher than the price for petroleum-based diesel. (In Brazil, diesel costs about $1 per liter.)
The average price—which...
Related Articles
By Matthew Herper, Stat | 07.01.2026
Researchers have created what they say may count as the first synthetic cell, and have started a public benefit corporation to share the technology with other scientists. It’s a piece of science that generates as many questions as answers. They...
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Emily Baumgaetner Nunn, The New York Times | 07.20.2026
The National Institutes of Health recently announced a remarkable achievement: the world’s largest database of human genomes, a repository of information that the agency says will help usher in a new era in personalized medicine.
Scientists are already developing clinical...
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...